NCT02657694 (REDEMPTION) is a clinical trial of Sofosbuvir+Ledipasvir in Hepatitis C, sponsored by FixHepC.

Who is sponsoring NCT02657694?

NCT02657694 is sponsored by FixHepC.

What drugs are being tested in NCT02657694?

Interventions in NCT02657694: Sofosbuvir+Ledipasvir, Sofosbuvir+Daclatasvir, Sofosbuvir+Velpatasvir.

What condition does NCT02657694 study?

NCT02657694 studies Hepatitis C.

Is NCT02657694 still recruiting?

NCT02657694 is currently status unknown. Last updated 16 February 2017.

Last reviewed 2017-02-16 · How we verify

NCT02657694: REDEMPTION

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods

Status unknown Last updated 16 February 2017

What this trial tests

trial testing Sofosbuvir+Ledipasvir in Hepatitis C in 10,000 participants. Status unknown.

Timeline

1 July 2015

Primary endpoint
1 January 2017

30 June 2018

Quick facts

Lead sponsor	FixHepC
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	10,000
Start date	1 July 2015
Primary completion	1 January 2017
Estimated completion	30 June 2018
Sites	1 location across Australia

Drugs / interventions tested

Sofosbuvir+Ledipasvir
Sofosbuvir+Daclatasvir
Sofosbuvir+Velpatasvir

Conditions studied

Hepatitis C — all drugs for Hepatitis C →

Sponsor

FixHepC

Who can join

Adults 18 to 82, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

REDEMPTION (Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods) is observing and collating the treatment course, safety profile, and outcomes of patients around the world who are choosing to self import generic versions of the Direct Acting Antivirals Sofosbuvir, Ledipasvir and Daclatasvir from countries like China, India and Bangladesh.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02657694 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by FixHepC
Last refreshed: 16 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02657694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing